## RGNX: REGENXBIO Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 3.7% below STRENGTH zone (4.0-10.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($11.50)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Voss Capital LP Boosts Stock Holdings in REGENXBIO Inc. $RGNX**
- Source: MarketBeat | 20251208T140951 | Somewhat-Bullish | Relevance: 99%
-  Voss Capital LP significantly increased its stake in REGENXBIO Inc. by 47.4% in the second quarter, now holding 575,000 shares valued at approximately $4.72 million. Despite this institutional buying, REGENXBIO's CEO and other insiders have been selling shares, reducing insider ownership to 12.79%. The company, which recently beat quarterly earnings estimates, receives a "Moderate Buy" consensus from analysts with a target price suggesting significant upside from its current trading price.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Chardan Capital | $52 | $52 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Chardan Capital | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- JPMORGAN CHASE & CO: 16.0% (+109.6%)
- Blackrock Inc.: 12.6% (-5.7%)
- Redmile Group, LLC: 9.3% (-1.7%)
- Vanguard Group Inc: 6.6% (-2.4%)
- State Street Corpora: 3.9% (+7.7%)

### Key Risks

1. Elevated short interest (11.4%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.26 indicates undervaluation relative to growth. Balance sheet: strong liquidity (2.7x). Revenue growth strong at 39% YoY. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $0.7B |
| Beta | 1.14 |
| 52W Range | $5.04 - $13.99 |
| Short Interest | 11.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.26 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from 6.5% to 3.7% (-2.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.3pp (needs >4.0% for momentum thesis). MRS_5 (-0.1%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 6.2% shows strong absolute momentum above own 20MA. Outperforming sector by 7.2pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 57.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.73% (CS: 75) | Neutral |
| RSI_14 | 57.4 | Neutral |
| MACD Histogram | 0.05 | Bullish |
| vs SMA20 | 1.062x | Above |
| vs SMA50 | 1.086x | Above |
| vs SMA200 | 1.407x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $13.06
- **Stop Loss:** $11.50 (11.9% risk)
- **Target:** $14.62 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 320
- **Position Value:** $4,179.20
- **Portfolio %:** 4.18%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-03-12 (Est: $-0.80)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.30 | $-1.20 | +7.6% |
| 2025Q2 | $-1.05 | $-1.38 | -30.8% |
| 2025Q1 | $0.49 | $0.12 | -75.3% |
| 2024Q4 | $-1.08 | $-1.01 | +6.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*